BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers

Area of Science:

• Oncology
• Genetics
• Cancer Predisposition

Background:

• Approximately 5-10% of breast and 10% of ovarian cancers stem from genetic susceptibility.
• About 40% of these hereditary cancers are linked to mutations in BRCA1 and BRCA2 genes.
• Genetic testing demand is rising, but currently restricted to high-risk families due to high penetrance.

Purpose of the Study:

• To review biological mechanisms of BRCA1 and BRCA2 dysfunction in cancer predisposition.
• To critically overview current genetic testing methods for BRCA mutations.
• To provide guidance on interpreting test results and managing mutation carriers.

Main Methods:

• Literature review of biological mechanisms.
• Critical analysis of current genetic testing methodologies.
• Synthesis of information on clinical management strategies.

Main Results:

• BRCA1/BRCA2 gene dysfunction is central to hereditary breast and ovarian cancer.
• Current genetic testing methods are detailed, with emphasis on their application in high-risk populations.
• Interpretation of genetic test outcomes and clinical management protocols are discussed.

Conclusions:

• Understanding BRCA1/BRCA2 dysfunction enhances knowledge of cancer predisposition.
• Genetic testing, though limited, plays a crucial role in identifying at-risk individuals.
• Effective clinical management is essential for BRCA mutation carriers to mitigate cancer risk.